"BRAF melanoma" trang 1 - tải miễn phí từ tailieunhanh
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
5    66    1
Ifferential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

Ifferential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
10    141    1
Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations
3    40    1
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
9    46    1
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: A case report

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: A case report
5    41    1
The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma
8    82    1
Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial

Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial
8    51    0
Báo cáo hóa học:

Báo cáo hóa học: " Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032"
3    51    0
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
7    37    1
Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care

Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care
12    39    1
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance
9    32    1
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
13    55    1
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
12    54    1
Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis

Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis
10    49    1
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
11    58    1
Case series: Indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma

Case series: Indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma
4    28    1
A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma

A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma
11    45    1
Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
4    54    1
Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials
6    45    0
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition
10    25    1